219 related articles for article (PubMed ID: 28030629)
1. Co-Activation of Th17 and Antibody Responses Provides Efficient Protection against Mucosal Infection by Group A Streptococcus.
Chen X; Li N; Bi S; Wang X; Wang B
PLoS One; 2016; 11(12):e0168861. PubMed ID: 28030629
[TBL] [Abstract][Full Text] [Related]
2. Sortase A induces Th17-mediated and antibody-independent immunity to heterologous serotypes of group A streptococci.
Fan X; Wang X; Li N; Cui H; Hou B; Gao B; Cleary PP; Wang B
PLoS One; 2014; 9(9):e107638. PubMed ID: 25232948
[TBL] [Abstract][Full Text] [Related]
3. A Multicomponent Vaccine Provides Immunity against Local and Systemic Infections by Group A Streptococcus across Serotypes.
Bi S; Xu M; Zhou Y; Xing X; Shen A; Wang B
mBio; 2019 Nov; 10(6):. PubMed ID: 31772056
[TBL] [Abstract][Full Text] [Related]
4. Active and passive intranasal immunizations with streptococcal surface protein C5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils.
Park HS; Cleary PP
Infect Immun; 2005 Dec; 73(12):7878-86. PubMed ID: 16299278
[TBL] [Abstract][Full Text] [Related]
5. Toll-like Receptors 2 and 4-Mediated Reciprocal Th17 and Antibody Responses to Group A Streptococcus Infection.
Wang X; Fan X; Bi S; Li N; Wang B
J Infect Dis; 2017 Feb; 215(4):644-652. PubMed ID: 28011917
[TBL] [Abstract][Full Text] [Related]
6. Local Th17/IgA immunity correlate with protection against intranasal infection with Streptococcus pyogenes.
Mortensen R; Christensen D; Hansen LB; Christensen JP; Andersen P; Dietrich J
PLoS One; 2017; 12(4):e0175707. PubMed ID: 28414746
[TBL] [Abstract][Full Text] [Related]
7. Clinical and microbiological response of mice to intranasal inoculation with Lactococcus lactis expressing Group A Streptococcus antigens, to be used as an anti-streptococcal vaccine.
García PC; Paillavil BA; Scioscia N; Dale JB; Legarraga P; Salazar-Echegarai FJ; Bueno SM; Kalergis AM; Wozniak A
Microbiol Immunol; 2018 Nov; 62(11):711-719. PubMed ID: 30357922
[TBL] [Abstract][Full Text] [Related]
8. Toward the development of an antidisease, transmission-blocking intranasal vaccine for group a streptococcus.
Batzloff MR; Yan H; Davies MR; Hartas J; Lowell GH; White G; Burt DS; Leanderson T; Good MF
J Infect Dis; 2005 Oct; 192(8):1450-5. PubMed ID: 16170764
[TBL] [Abstract][Full Text] [Related]
9. Differing Efficacies of Lead Group A Streptococcal Vaccine Candidates and Full-Length M Protein in Cutaneous and Invasive Disease Models.
Rivera-Hernandez T; Pandey M; Henningham A; Cole J; Choudhury B; Cork AJ; Gillen CM; Ghaffar KA; West NP; Silvestri G; Good MF; Moyle PM; Toth I; Nizet V; Batzloff MR; Walker MJ
mBio; 2016 Jun; 7(3):. PubMed ID: 27302756
[TBL] [Abstract][Full Text] [Related]
10. Self-adjuvanting modular virus-like particles for mucosal vaccination against group A streptococcus (GAS).
Rivera-Hernandez T; Hartas J; Wu Y; Chuan YP; Lua LH; Good M; Batzloff MR; Middelberg AP
Vaccine; 2013 Apr; 31(15):1950-5. PubMed ID: 23422147
[TBL] [Abstract][Full Text] [Related]
11. Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections.
Hall MA; Stroop SD; Hu MC; Walls MA; Reddish MA; Burt DS; Lowell GH; Dale JB
Infect Immun; 2004 May; 72(5):2507-12. PubMed ID: 15102757
[TBL] [Abstract][Full Text] [Related]
12. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
[TBL] [Abstract][Full Text] [Related]
13. Intranasal immunization with serum opacity factor (SOF) of Streptococcus pyogenes fails to protect mice against lethal mucosal challenge with a heterologous strain.
Schulze K; Medina E; Guzmán CA
Vaccine; 2006 Feb; 24(9):1446-50. PubMed ID: 16289766
[TBL] [Abstract][Full Text] [Related]
14. Bivalent mucosal peptide vaccines administered using the LCP carrier system stimulate protective immune responses against Streptococcus pyogenes infection.
Schulze K; Ebensen T; Chandrudu S; Skwarczynski M; Toth I; Olive C; Guzman CA
Nanomedicine; 2017 Nov; 13(8):2463-2474. PubMed ID: 28887213
[TBL] [Abstract][Full Text] [Related]
15. Modular virus-like particles for sublingual vaccination against group A streptococcus.
Seth A; Kong IG; Lee SH; Yang JY; Lee YS; Kim Y; Wibowo N; Middelberg AP; Lua LH; Kweon MN
Vaccine; 2016 Dec; 34(51):6472-6480. PubMed ID: 27866769
[TBL] [Abstract][Full Text] [Related]
16. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.
Olive C; Ho MF; Dyer J; Lincoln D; Barozzi N; Toth I; Good MF
J Infect Dis; 2006 Jun; 193(12):1666-76. PubMed ID: 16703510
[TBL] [Abstract][Full Text] [Related]
17. Immunogenic characterization and protection against Streptococcus mutans infection induced by intranasal DNA prime-protein boost immunization.
Li YH; Huang S; Du M; Bian Z; Chen Z; Fan MW
Vaccine; 2010 Jul; 28(32):5370-6. PubMed ID: 20573581
[TBL] [Abstract][Full Text] [Related]
18. Immunization with C5a peptidase from either group A or B streptococci enhances clearance of group A streptococci from intranasally infected mice.
Cleary PP; Matsuka YV; Huynh T; Lam H; Olmsted SB
Vaccine; 2004 Oct; 22(31-32):4332-41. PubMed ID: 15474726
[TBL] [Abstract][Full Text] [Related]
19. Induction of TGF-beta1 and TGF-beta1-dependent predominant Th17 differentiation by group A streptococcal infection.
Wang B; Dileepan T; Briscoe S; Hyland KA; Kang J; Khoruts A; Cleary PP
Proc Natl Acad Sci U S A; 2010 Mar; 107(13):5937-42. PubMed ID: 20231435
[TBL] [Abstract][Full Text] [Related]
20. Liposome-based intranasal delivery of lipopeptide vaccine candidates against group A streptococcus.
Ghaffar KA; Marasini N; Giddam AK; Batzloff MR; Good MF; Skwarczynski M; Toth I
Acta Biomater; 2016 Sep; 41():161-8. PubMed ID: 27063491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
